Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7057388 | 0.98 | — | — | |
| SCHEMBL24311272 | 0.88 | MMP2 (0.31) | MMP2ANPEPPOLB | |
| SCHEMBL26802328 | 0.88 | MMP2 (0.31) | MMP2ANPEPPOLB | |
| SCHEMBL28976122 | 0.86 | — | — | |
| SCHEMBL18118845 | 0.86 | — | — | |
| SCHEMBL14474241 | 0.85 | — | — | |
| SCHEMBL26802597 | 0.85 | — | — | |
| SCHEMBL2726402 | 0.85 | — | — | |
| SCHEMBL30053600 | 0.85 | — | — | |
| SCHEMBL9908179 | 0.84 | MMP2 (0.32) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4214331-B1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | BRUKER SPATIAL BIOLOGY INC (US) | 2025-06-18 | — | — | EP | claimed |
| CN-112703399-B | Methods and compositions for removing biotin interference from assays using molecular traps | 美国西门子医学诊断股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| EP-4425179-A2 | COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE | Life Technologies Corporation (US) | 2024-09-04 | — | — | EP | claimed |
| EP-4381088-A1 | SYSTEMS AND METHODS FOR ANTIBODY CHAIN PAIRING | Rapid Novor Inc. (CA) | 2024-06-12 | — | — | EP | claimed |
| CN-117795090-A | Systems and methods for antibody chain pairing | 快速诺凡公司 | 2024-03-29 | — | — | CN | claimed |
| EP-3507603-B1 | COMPOSITIONS AND METHODS FOR ENHANCED FLUORESCENCE | LIFE TECHNOLOGIES CORP (US) | 2024-03-06 | — | — | EP | claimed |
| US-11865191-B2 | Compositions and methods for enhanced fluorescence | Life Technologies Corporation (US) | 2024-01-09 | — | — | US | claimed |
| US-11857643-B2 | Compositions and methods for enhanced fluorescence | Life Technologies Corporation (US) | 2024-01-02 | — | — | US | claimed |
| CN-117120629-A | Chemical compositions and methods of use thereof | 纳米线科技公司 | 2023-11-24 | — | — | CN | claimed |
| US-20230366012-A1 | CHEMICAL COMPOSITIONS AND METHODS OF USING THE SAME | BRUKER SPATIAL BIOLOGY, INC. | 2023-11-16 | — | — | US | claimed |
| EP-3194964-B1 | MULTIFUNCTIONAL PROTEIN MOLECULAR WEIGHT STANDARDS | LI COR INC (US) | 2021-10-27 | — | — | EP | claimed |
| CN-112703401-A | Methods and compositions for removing biotin interference from assays using conjugated molecular traps | 美国西门子医学诊断股份有限公司 | 2021-04-23 | — | — | CN | claimed |
| US-8071288-B2 | Solid phase synthesis; photocrosslinking; binds specifically to HIV gp120; biochips | SOMALOGIC, INC. (US) | 2011-12-06 | — | — | US | claimed |
| US-20100003701-A1 | COVALENT MODIFICATION AND CONJUGATION OF LUCIFERASE | CARDIOGENICS INC. (CA) | 2010-01-07 | — | — | US | claimed |
| US-20080160535-A1 | Methods and Reagents for Detecting Target Binding by Nucleic Acid Ligands | SOMALOGIC, INC. (US) | 2008-07-03 | — | — | US | claimed |
| US-20070254311-A1 | Covalent modification and conjugation of luciferase | CARDIOGENICS INC. (CA) | 2007-11-01 | — | — | US | claimed |
| US-20060057573-A1 | Methods and reagents for detecting target binding by nucleic acid ligands | SOMALOGIC, INC (US) | 2006-03-16 | — | — | US | claimed |
| EP-1481090-A1 | METHODS AND REAGENTS FOR DETECTING TARGET BINDING BY NUCLEIC ACID LIGANDS | SomaLogic, Inc. (US) | 2004-12-01 | — | — | EP | claimed |
| WO-2003070984-A1 | METHODS AND REAGENTS FOR DETECTING TARGET BINDING BY NUCLEIC ACID LIGANDS | SOMALOGIC, INC. (US) | 2003-08-28 | — | — | WO | claimed |
| WO-2001005948-A1 | ASSAY OF THE ACTIVATION STATE OF PLATELETS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2001-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11857643-B2 | Compositions and methods for enhanced fluorescence | ANXA5, HNRNPF, ANXA6 | MMP2 4478/4885ANPEP 2941/4885POLB 2057/4885 |
| US-11865191-B2 | Compositions and methods for enhanced fluorescence | ANXA5, HNRNPF, ANXA6 | MMP2 4478/4885ANPEP 2941/4885POLB 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.